Literature DB >> 15931172

Haemophilia A: from mutation analysis to new therapies.

Jochen Graw1, Hans-Hermann Brackmann, Johannes Oldenburg, Reinhard Schneppenheim, Michael Spannagl, Rainer Schwaab.   

Abstract

Haemophilia is caused by hundreds of different mutations and manifests itself in clinical conditions of varying severity. Despite being inherited in monogenic form, the clinical features of haemophilia can be influenced by other genetic factors, thereby confounding the boundary between monogenic and multifactorial disease. Unlike sufferers of other genetic diseases, haemophiliacs can be treated successfully by intravenous substitution of coagulation factors. Haemophilia is also the most attractive model for developing gene-therapy protocols, as the normal life expectancy of haemophiliacs allows the side effects of gene therapy, as well as its efficiency, to be monitored over long periods.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15931172     DOI: 10.1038/nrg1617

Source DB:  PubMed          Journal:  Nat Rev Genet        ISSN: 1471-0056            Impact factor:   53.242


  35 in total

1.  Identification of novel mutations in exon 14 of the f8 gene in malaysian patients with severe hemophilia a.

Authors:  Emmanuel Jairaj Moses; Sim Pei Ling; Faisal Muti Al-Hassan; Faraizah Abdul Karim; Narazah Mohd Yusoff
Journal:  Indian J Clin Biochem       Date:  2011-09-30

2.  Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia A.

Authors:  Cristina Olgasi; Maria Talmon; Simone Merlin; Alessia Cucci; Yvonne Richaud-Patin; Gabriella Ranaldo; Donato Colangelo; Federica Di Scipio; Giovanni N Berta; Chiara Borsotti; Federica Valeri; Francesco Faraldi; Maria Prat; Maria Messina; Piercarla Schinco; Angelo Lombardo; Angel Raya; Antonia Follenzi
Journal:  Stem Cell Reports       Date:  2018-11-08       Impact factor: 7.765

3.  Targeted chromosomal duplications and inversions in the human genome using zinc finger nucleases.

Authors:  Hyung Joo Lee; Jiyeon Kweon; Eunji Kim; Seokjoong Kim; Jin-Soo Kim
Journal:  Genome Res       Date:  2011-12-19       Impact factor: 9.043

Review 4.  Haemophilia management: time to get personal?

Authors:  T E Howard; C Yanover; J Mahlangu; A Krause; K R Viel; C K Kasper; K P Pratt
Journal:  Haemophilia       Date:  2011-06-08       Impact factor: 4.287

5.  Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs.

Authors:  Chul-Yong Park; Jungeun Kim; Jiyeon Kweon; Jeong Sang Son; Jae Souk Lee; Jeong-Eun Yoo; Sung-Rae Cho; Jong-Hoon Kim; Jin-Soo Kim; Dong-Wook Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-09       Impact factor: 11.205

6.  Blood coagulation factors V and VIII: Molecular Mechanisms of Procofactor Activation.

Authors:  Mettine H A Bos; Rodney M Camire
Journal:  J Coagul Disord       Date:  2010-07-01

7.  Complexity and diversity of F8 genetic variations in the 1000 genomes.

Authors:  J N Li; I G Carrero; J F Dong; F L Yu
Journal:  J Thromb Haemost       Date:  2015-10-20       Impact factor: 5.824

8.  Rapid genotyping of F8 intron 22 inversion by nested PCR based on long-distance PCR.

Authors:  Xiong Wang; Weihong Hu; Yong Gao; Dengju Li; Yanjun Lu
Journal:  J Thromb Thrombolysis       Date:  2020-05       Impact factor: 2.300

9.  Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells.

Authors:  Alexandra Sherman; Jin Su; Shina Lin; Xiaomei Wang; Roland W Herzog; Henry Daniell
Journal:  Blood       Date:  2014-05-13       Impact factor: 22.113

10.  Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients.

Authors:  Kathelijn Fischer; Ronan Pendu; Carina J van Schooten; Karin van Dijk; Cécile V Denis; H Marijke van den Berg; Peter J Lenting
Journal:  PLoS One       Date:  2009-08-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.